UroToday.com· @urotoday · X·· 2 天前评分70
正文 · 原文
Capivasertib + Abiraterone vs Placebo + Abiraterone in Patients with PTEN-Deficient #mHSPC: Updated Overall Survival from CAPItello-281. Presented by @fizazi_karim @GustaveRoussy. #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4iDxpio #ProstateCancer @myESMO
350 浏览 · 2 赞 · 4 转发 · 0 回复
会议摘要
Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281
https://esmocongress.esmo.org来源：UroToday.com · x.com